## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

Claim 1 (currently amended): A method of suppressing a respiratory syncytial virus (RSV) infection in an individual who has been exposed to RSV, comprising administering a composition to the respiratory tract of said individual, said composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5'-CG-3', wherein the polynucleotide is greater than 6 and less than about 200 nucleotides in length, wherein RSV antigen, an immunostimulatory cytokine, and an non-nucleic acid adjuvant are not administered in conjunction with administration of said composition, wherein the individual is a human and wherein said composition is administered in an amount sufficient to suppress an RSV infection.

Claim 2 (original): The method of claim 1, wherein the ISS comprises the sequence 5'-T, C, G-3'.

Claim 3 (original): The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.

Claim 4 (original): The method of claim 3, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3', and 5'-GACGTTCG-3'.

Claim 5 (original): The method of claim 1, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).

Claim 6-7 (cancelled)

Docket No.: 377882000900

Claim 8 (previously presented): The method of claim 1, wherein administration is to a lung.

Claim 9 (previously presented): The method of claim 1, wherein administration is to the nasal passages.

Claim 10 (original): The method of claim 1, wherein the suppression comprises a reduction of RSV titer in a biological sample from said individual.

Claims 11-15 (cancelled)

Claim 16 (new): The method of claim 1, wherein the polynucleotide comprises a phosphate backbone modification.

Claim 17 (new): The method of claim 1 wherein said composition comprises a ISS-containing polynucleotide and a pharmaceutically-acceptable excipient and wherein said composition excludes immunoregulatory agents and immunostimulatory cytokines.